Bisht Priya, Dagar Neha, Kumar Nitesh, Velayutham Ravichandiran, Arumugam Somasundaram
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER-Hajipur, Export Promotion Industrial Park (EPIP), Zandaha Road, NH322, Hajipur, Bihar 844102, India.
Department of Pharmacology and Toxicology, Birla Institute of Technology and Science, Pilani Campus, Vidya Vihar, Pilani 333031, Rajasthan, India.
Curr Drug Targets. 2023;24(3):247-260. doi: 10.2174/1389450124666221209123541.
Constipation is one of the most frequent abnormalities of the gastrointestinal system that affects the patient's quality of life. Constipation is more common in women and affects them more frequently as they get older. Many constipated patients take over-the-counter drugs for treatment, but some do not respond to these medicines and need newer, more expensive drugs. Still, many patients are not completely satisfied with these medicines. Unlike other areas, constipation research is not given much importance.
This review discusses targets such as ClC-2, CFTR, opioid receptors, and 5HT-4 receptors, which are important in constipation therapy. The recent focus is also on the gut microbiome with the help of various randomized controlled trials. Pharmacological advances have also added novel targets such as IBAT, PAR-2, and intestinal NHE-3 for constipation treatment.
This review summarises the research on these targets collected from various databases. ClC-2 and CFTR are involved in intestinal chloride secretion followed by sodium or water, which increases stool passage. Non-cancer pain treatment with opioids targeting opiate receptors is considered in 40-90% of patients, which causes constipation as a side effect. On activation, 5HT-4 receptors increase gastrointestinal motility. IBAT is responsible for transporting bile acid into the liver. Bile acid will reach the colon by inhibiting IBAT, stimulating colonic motility, and providing a laxative effect. Activation of the ghrelin receptor results in prokinetic activity in both animals and humans. Intestinal NHE-3 mediates the absorption of Na+ and the secretion of hydrogen into the intestine. Many reports show that PAR-2 is involved in the pathogenesis of gastrointestinal diseases. The gut microbiota influences the peristaltic action of the intestine.
Drugs working on these targets positively impact the treatment of constipation, as do the drugs that are currently in clinical trials acting on these targets. The results from the ongoing clinical trials will also provide some valuable information regarding whether these medications will meet the patients' needs in the future.
便秘是影响患者生活质量的最常见的胃肠系统异常之一。便秘在女性中更为常见,且随着年龄增长,女性受其影响的频率更高。许多便秘患者服用非处方药物进行治疗,但有些患者对这些药物没有反应,需要更新、更昂贵的药物。然而,许多患者对这些药物并不完全满意。与其他领域不同,便秘研究未受到足够重视。
本综述讨论了在便秘治疗中重要的靶点,如氯离子通道蛋白2(ClC-2)、囊性纤维化跨膜传导调节因子(CFTR)、阿片受体和5-羟色胺4(5HT-4)受体。近期借助各种随机对照试验,研究重点也放在了肠道微生物群上。药理学进展还为便秘治疗增加了新的靶点,如肠道胆汁酸转运蛋白(IBAT)、蛋白酶激活受体-2(PAR-2)和肠道钠/氢交换体3(NHE-3)。
本综述总结了从各种数据库收集的关于这些靶点的研究。ClC-2和CFTR参与肠道氯分泌,随后是钠或水的分泌,这会增加粪便排出。40%至90%的患者使用针对阿片受体的阿片类药物治疗非癌性疼痛,这会导致便秘作为副作用。5HT-4受体激活后会增加胃肠动力。IBAT负责将胆汁酸转运到肝脏。通过抑制IBAT,胆汁酸会到达结肠,刺激结肠动力,并产生通便作用。胃饥饿素受体的激活在动物和人类中均会导致促动力活性。肠道NHE-3介导钠的吸收和氢分泌到肠道中。许多报告表明PAR-2参与胃肠疾病的发病机制。肠道微生物群影响肠道的蠕动作用。
作用于这些靶点的药物对便秘治疗有积极影响,目前正在进行的针对这些靶点的临床试验药物也是如此。正在进行的临床试验结果也将提供一些关于这些药物未来是否能满足患者需求的有价值信息。